bioRxiv · 10.1101/535302
Extremely Drug-Resistant Pseudomonas aeruginosa ST309 Harboring Tandem GES Enzymes: A Newly Emerging Threat in the United States
Abstract
Two ST309 Pseudomonas aeruginosa clinical isolates resistant to carbapenems and newer {beta}-lactam/{beta}-lactamase inhibitor combinations were found to harbor the extended spectrum beta-lactamases GES 19 and 26 genetically clustered in tandem. The combination of ceftazidime/avibactam plus aztreonam achieved cure in one patient. Phylogenetic analysis suggests that ST309 P. aeruginosa carrying tandem GES are an emerging lineage in the United States.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Khan, A., Tran, T. T., Rios, R., Hanson, B., Shropshire, W. C., Sun, Z., Diaz, L., Dinh, A. Q., Wanger, A., Ostrosky-Zeichner, L., Palzkill, T., Arias, C. A., Miller, W. R.. 2019-01-30. Extremely Drug-Resistant Pseudomonas aeruginosa ST309 Harboring Tandem GES Enzymes: A Newly Emerging Threat in the United States. https://doi.org/10.1101/535302
Cite the original work for its findings. Save a collection to share your selection of sources.